Source: Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Glick, A. Briggs, G. Lozano-Ortega, M. Spencer, P. Calverley, J. Vestbo (Philadelphia, United States Of America; Glasgow, Greenford, Liverpool, Manchester, United Kingdom; Vancouver, Canada). Is treatment with ICS and LABA good value for money for COPD? Multinational cost-effectiveness analysis of the TORCH study. Eur Respir J 2007; 30: Suppl. 51, 1189

Member's Comments

No comment yet.

Related content which might interest you: Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study Source: Eur Respir J 2010; 35: 532-539 Year: 2010 Comparison of cardiovascular safety in a pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial Source: Annual Congress 2009 - Functional insights into COPD Year: 2009 Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 AUSTRI and VESTRI LABA Safety studies subgroup analysis of asthma exacerbations and SAEs comparing FSC and FP by ICS dose Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 Safety and effectiveness of indacaterol in Korean COPD patients: A post-marketing surveillance (PMS) study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 The cost-effectiveness of early intervention with inhaled budesonide once daily: an international comparison of the results from the START study Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002 Health care resource utilization following addition of montelukast or salmeterol to fluticasone in patients with inadequately controlled asthma (IMPACT trial) Source: Eur Respir J 2004; 24: Suppl. 48, 127s Year: 2004 COPD patients continuing salmeterol or switched to tiotropium: a retrospective analysis of clinical trial data Source: Eur Respir J 2007; 30: Suppl. 51, 612s Year: 2007 Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial Source: ERJ Open Res, 8 (1) 00333-2021; 10.1183/23120541.00333-2021 Year: 2022 Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial Source: Eur Respir J 2013; 41: 556-564 Year: 2013 Cost effectiveness of budesonide/formoterol vs fluticasone/salmeterol: Real-world effectiveness and safety in COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Safety of long-acting β-agonist (LABA) withdrawal in patients in two clinical asthma trials Source: Annual Congress 2012 - Different ways to phenotype asthma Year: 2012 The effect of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A real practice analysis in Italy Source: International Congress 2014 – Prevalence of COPD and mortality from COPD Year: 2014 A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD Source: Annual Congress 2013 –Risk factors for COPD and lung function decline Year: 2013 Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design Source: ERJ Open Res, 5 (4) 00061-2019; 10.1183/23120541.00061-2019 Year: 2019 Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Assessment of efficacy and tolerability of roflumilast add-on to LABA/LAMA/ICS in the treatment of COPD in Indian patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016